US Stock MarketDetailed Quotes

RAPP Rapport Therapeutics

Watchlist

20.120
-2.910-12.64%

Close Jul 19 16:00 ET

20.500
+0.380+1.89%

Post 18:33 ET

735.92MMarket Cap-13875P/E (TTM)

Rapport Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual

YOY

Hide blank lines

(Q1)Mar 31, 2024

(FY)Dec 31, 2023

(Q1)Mar 31, 2023

Operating Cash Flow (Indirect Method)

Cash flow from continuing operating activities

-266.90%-17.62M

-27.18M

-4.8M

Net income from continuing operations

-268.78%-22.67M

---34.79M

---6.15M

Operating gains losses

617.48%7.39M

--1.12M

--1.03M

Depreciation and amortization

913.33%152K

--112K

--15K

Other non cash items

--156K

--267K

----

Change In working capital

-648.10%-3.16M

--2.65M

---422K

-Change in prepaid assets

-241.58%-2.07M

---3.2M

---606K

-Change in payables and accrued expense

-367.70%-953K

--6.24M

--356K

-Change in other current assets

115.70%27K

---240K

---172K

-Change in other current liabilities

---161K

---144K

--0

Cash from discontinued investing activities

Operating cash flow

-266.90%-17.62M

---27.18M

---4.8M

Investing cash flow

Cash flow from continuing investing activities

-68,631.15%-41.93M

-78.86M

-61K

Net PPE purchase and sale

-1,657.38%-1.07M

---1.64M

---61K

Net investment purchase and sale

---40.85M

---77.22M

--0

Cash from discontinued investing activities

Investing cash flow

-68,631.15%-41.93M

---78.86M

---61K

Financing cash flow

Cash flow from continuing financing activities

6.09%63.66M

145.14M

60.01M

Net issuance payments of debt

----

--0

----

Net common stock issuance

--0

--50K

--24K

Net preferred stock issuance

6.57%63.94M

--145.22M

--60M

Net other financing activities

-1,472.22%-283K

---134K

---18K

Cash from discontinued financing activities

Financing cash flow

6.09%63.66M

--145.14M

--60.01M

Net cash flow

Beginning cash position

125.47%70.25M

--31.16M

Current changes in cash

-92.53%4.12M

--39.1M

--55.14M

End cash Position

-13.82%74.37M

--70.25M

--86.3M

Free cash flow

-284.35%-18.69M

---28.82M

---4.86M

Currency Unit

USD

Audit Opinions

Unqualified Opinion

	(Q1)Mar 31, 2024	(FY)Dec 31, 2023	(Q1)Mar 31, 2023
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities	-266.90%-17.62M	-27.18M	-4.8M
Net income from continuing operations	-268.78%-22.67M	---34.79M	---6.15M
Operating gains losses	617.48%7.39M	--1.12M	--1.03M
Depreciation and amortization	913.33%152K	--112K	--15K
Other non cash items	--156K	--267K	----
Change In working capital	-648.10%-3.16M	--2.65M	---422K
-Change in prepaid assets	-241.58%-2.07M	---3.2M	---606K
-Change in payables and accrued expense	-367.70%-953K	--6.24M	--356K
-Change in other current assets	115.70%27K	---240K	---172K
-Change in other current liabilities	---161K	---144K	--0
Cash from discontinued investing activities
Operating cash flow	-266.90%-17.62M	---27.18M	---4.8M
Investing cash flow
Cash flow from continuing investing activities	-68,631.15%-41.93M	-78.86M	-61K
Net PPE purchase and sale	-1,657.38%-1.07M	---1.64M	---61K
Net investment purchase and sale	---40.85M	---77.22M	--0
Cash from discontinued investing activities
Investing cash flow	-68,631.15%-41.93M	---78.86M	---61K
Financing cash flow
Cash flow from continuing financing activities	6.09%63.66M	145.14M	60.01M
Net issuance payments of debt	----	--0	----
Net common stock issuance	--0	--50K	--24K
Net preferred stock issuance	6.57%63.94M	--145.22M	--60M
Net other financing activities	-1,472.22%-283K	---134K	---18K
Cash from discontinued financing activities
Financing cash flow	6.09%63.66M	--145.14M	--60.01M
Net cash flow
Beginning cash position	125.47%70.25M	--31.16M	--31.16M
Current changes in cash	-92.53%4.12M	--39.1M	--55.14M
End cash Position	-13.82%74.37M	--70.25M	--86.3M
Free cash flow	-284.35%-18.69M	---28.82M	---4.86M
Currency Unit	USD	USD	USD
Audit Opinions	--	Unqualified Opinion	--

Analysis

Analyst Rating

No Data

Price Target

No Data

Overall